- Home
- LFWD vs NERV Comparison
LFWD vs NERV Comparison
Compare LFWD & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFWD
- NERV
- Stock Information
- Founded
- LFWD 2001
- NERV 2007
- Country
- LFWD Israel
- NERV United States
- Employees
- LFWD N/A
- NERV N/A
- Industry
- LFWD
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- LFWD
- NERV Health Care
- Exchange
- LFWD NYSE
- NERV Nasdaq
- Market Cap
- LFWD 11.8M
- NERV 12.6M
- IPO Year
- LFWD 2014
- NERV 2014
- Fundamental
- Price
- LFWD $0.68
- NERV $1.65
- Analyst Decision
- LFWD Strong Buy
- NERV Hold
- Analyst Count
- LFWD 3
- NERV 1
- Target Price
- LFWD $9.00
- NERV $5.00
- AVG Volume (30 Days)
- LFWD 1.4M
- NERV 6.6K
- Earning Date
- LFWD 08-14-2025
- NERV 08-05-2025
- Dividend Yield
- LFWD N/A
- NERV N/A
- EPS Growth
- LFWD N/A
- NERV N/A
- EPS
- LFWD N/A
- NERV 0.83
- Revenue
- LFWD $25,414,000.00
- NERV N/A
- Revenue This Year
- LFWD $12.04
- NERV N/A
- Revenue Next Year
- LFWD $40.58
- NERV N/A
- P/E Ratio
- LFWD N/A
- NERV $2.00
- Revenue Growth
- LFWD 41.92
- NERV N/A
- 52 Week Low
- LFWD $0.50
- NERV $1.15
- 52 Week High
- LFWD $4.77
- NERV $3.50
- Technical
- Relative Strength Index (RSI)
- LFWD 26.18
- NERV 50.22
- Support Level
- LFWD $0.60
- NERV $1.57
- Resistance Level
- LFWD $0.73
- NERV $1.88
- Average True Range (ATR)
- LFWD 0.09
- NERV 0.09
- MACD
- LFWD -0.03
- NERV -0.02
- Stochastic Oscillator
- LFWD 25.26
- NERV 52.03
About LFWD REWALK ROBOTICS LTD
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.